RE:RE:why it is very risky to invest?
This is nearly following William Hunter's playbook with angiotech some years ago: develop a drug product with decent sales, expand through acquisitions taking on debt at high interest that were out of line with reasonable profit projections, and then having the lenders acquire it to settle the debt. Compared to ANP at least you guys get your 42 cents. ANP paid the shareholders nothing. In both cases they are companies with established products and management pursuing their own agenda, and the drug assets are irrelevant to this manouver. Pretty predictable.